We will review the diagnosis, recognition, and management of PNH, and specifically in the context of the Canadian treatment landscape. Cases will be used to highlight the variable presentations of thrombotic complications. We encourage interactivity and provide the ability to participate in Q&A, polling, and other engagement opportunities.

Speaker: Christopher Patriquin MD MSc FRCPC
Hematology & Apheresis Medicine, University Health Network
Assistant Professor of Medicine, University of Toronto

Learning Objectives

• Review the differential diagnosis of hemolytic anemias
• Discuss the recognition, diagnosis, and general management of paroxysmal nocturnal hemoglobinuria (PNH)
• Understand the pathophysiology, risk, and treatment of PNH-associated thromboembolism
• Explore novel therapies for PNH and their implications

Accreditation: This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists (CAP-AC). You may claim a maximum of 1.0 hours. Certificates of Attendance will be sent to all CHS members who participate.

Conflict of Interest:

• Speaking and advisory board honoraria: Alexion and SOBI
• Advisory board honoraria: Apellis; BioCryst; Novartis; Roche; Sanofi; Takeda

CANMED Roles:
Medical Expert (the integrating role)
Communicator
Collaborator
Leader
Health Advocate
Scholar
Professional

Target Audience:

Hematologists, Residents, Internists, ER Physicians

This webinar is supported by a grant from Alexion and the CHS Scientific Planning Committee has planned it to achieve scientific integrity, objectivity and balance.